Investment news reveals a variety of developments for Laboratory Corporation of America Holdings (Labcorp, NYSE:LH). The company continues to display rising relative strength, despite not reaching a key performance threshold. Quarterly estimates have been consistently beaten due to strong testing demand. Labcorp has secured a winning bid for select assets of Invitae and has announced a strategic acquisition of certain BioReference Health Diagnostics assets. The company also scored mixed Q4 2023 results and announced expansion of strategic alliances. In terms of stock market performance, several institutions have adjusted their positions in Labcorp equity. While Zürcher Kantonalbank and Highland Capital Management have reduced their holdings, BNP Paribas Asset Management and Bank of New York Mellon Corp have boosted theirs. Furthermore, collaborations are noticeable in Labcorp's operations. The most significant involves Community Clinical Oncology Research Network to assess socio-economic impacts of cancer care disparities. Labcorp has also teamed up with Hawthorne Effect to bring clinical trials directly to local communities. In the corporate leadership realm, Labcorp executives have been trading company stock. However, the company's strategic development segment spinoff poised to generate significant value, with Labcorp aiming to assess preeclampsia risks using a new test.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 24 Oct 2016 07:00:00 GMT to Sun, 01 Sep 2024 08:38:23 GMT -
Rating 7
- Innovation 4
- Information 5
- Rumor 3
